JTV-519 (K201) is a Ca2+-dependent blocker of SERCA and a partial agonist of ryanodine receptors (RyRs).

JTV-519 (K201) is a Ca2+-dependent blocker of SERCA and a partial agonist of ryanodine receptors (RyRs).

JTT-553 is a novel potent, selective DGAT-1 inhibitor with IC50 of 2.38 nM, shows no inhibitory activity for human DGAT2 and ACA T1 (IC50>10 uM).

JTT-553 is a novel potent, selective DGAT-1 inhibitor with IC50 of 2.38 nM, shows no inhibitory activity for human DGAT2 and ACA T1 (IC50>10 uM).

JTT-551 sodium (JTT551, JTT 551) is a novel potent, selective inhibitor of protein tyrosine phosphatase 1B (PTP1B) with Ki of 0.22 uM, displays >45-fold and >136-fold selectivity over TCPTP, CD45 and LAR.

JTT-551 (JTT551, JTT 551) is a novel potent, selective inhibitor of protein tyrosine phosphatase 1B (PTP1B) with Ki of 0.22 uM, displays >45-fold and >136-fold selectivity over TCPTP, CD45 and LAR.

JTP-117968 is a novel orally available, selective glucocorticoid receptor modulator (SGRM) with IC50 of 6.8 nM.

JTE-952 (JTE952) is a potent, selective colony stimulating factor-1 receptor (CSF1R) type II inhibitor with IC50 of 14 nM, shows cellular activity in BMMCs IL-6 secretion assays with IC50 of 20 nM.

JSF-4088 (JSF4088) is a novel antitubercular agent with potent in vitro antitubercular potency (MIC=19 nM), with no significant Vero cell cytotoxicity (CC50 >120 uM)..

JQ1-VHL-PROTAC is a novel PROTAC synthesis..

JPI-289 (JPI289) is a novel potent, water soluble PARP-1 inhibitor with IC50 of 18.5 nM, inhibits cellular PAR formation with IC50 of 10.7 nM.

JPC-3210 is a potent antimalarial agent with IC50 of 2.5-19 nM, remains activity against multidrug-resistant Plasmodium falciparum lines with little cytotoxicity in mammalian cell lines.

JNJ-55511118 (JNJ55511118) is a selective, orally available AMPA receptor containing TARP-γ8 negative modulator with Ki of 26 nM, displays no significant activity against other TARP-less AMPARs and AMPARs coexpressed with other TARPs or CNIH2.

JNJ-55308942 is a novel highly potent P2X7 antagonist with Ki of 1.0 and 6.5 nM for rat and human hP2X7, demonstrates significant activity against a panel of related P2X receptors (P2X1, P2X2, P2X3, P2X2/3, and P2X4.

JNJ-5234801 is an atypical anxiolytic targeting 5-HT2 receptor, has demonstrated oral activity in animal models of anxiety..

JNJ-4929821 is a potent, reversible methionine aminopeptidase-2 (MetAP-2) inhibitor with IC50 of 8 nM..

JNJ-49095397 (RV-568) is a specific narrow-spectrum kinase inhibitor that inhibits a selected set of kinases involved in COPD inflammation with IC50 of 5, 40 and 52 nM for p38α, p38γ and HCK, respectively.

JNJ-42905343 is a potent, selective, orally active prolyl hydroxylase (PHD) inhibitor with pKi of 8.07, 7.48 and 7.27 for PHD1, PHD2 and PHD3 respectively.

JNJ-42314415(JNJ42314415) is a potent, selective, centrally active phosphodiesterase 10A (PDE10A) inhibitor with Ki of 35 nM for human recombinant PDE10A.

JNJ-40413269 is a potent, selective, blood brain barrier (BBB) penetrant FAAH inhibitor with IC50 of 5.3 and 6.3 nM for hFAAH and rFAAH, respectively.

JNJ-40279486 is a potent, selective histamine H4 receptor antagonist with Ki of 9.4 nM (hH4), demonstrates acceptable pharmacokinetic profile and efficacy in mouse model of inflammation..

JNJ-39933673 is a potent, selective SGLT2 inhibitor..

JNJ-39933673 hemihydrate is a potent, selective SGLT2 inhibitor..

JNJ-39729209 is a potent, selective TRPV1 antagonist with binding pKi of 7.8 and 7.9 for human and rat TRPV1, respectively.

JNJ-39393406 is a potent, selective positive allosteric α7 nAChR modulator, potentiates a 100 μM choline-induced rise in intracellular calcium mediated by human α7 channels expressed in GH4C1 cells with EC50 of 660 nM.

JNJ-38893777 is a potent and selective transient receptor potential vanilloid 1 (TRPV1) channel antagonist for treatment of ociceptive and neuropathic pain..

JNJ-38893777 is a potent and selective transient receptor potential vanilloid 1 (TRPV1) channel antagonist for treatment of ociceptive and neuropathic pain..

JNJ-38877618 (OMO-1) is a novel potent, highly selective, orally bioavailable c-Met tyrosine kinase inhibitor with Kd of 1.2, 2.1 and 21 nM for WT, M1250T and Y1235D mutants MET, respectively.

JNJ-37822681 is a potent, specific and fast-dissociating dopamine D2 antagonist with Ki of 158 nM.

JNJ-28610244 is a potent, selective agonist of histamine H4 receptor (H4R)..